453 related articles for article (PubMed ID: 25072780)
21. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
[TBL] [Abstract][Full Text] [Related]
22. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
Stewart DA; Bahlis N; Mansoor A
Leuk Lymphoma; 2009 Aug; 50(8):1276-82. PubMed ID: 19562614
[TBL] [Abstract][Full Text] [Related]
23. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
24. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.
Arnason JE; Luptakova K; Rosenblatt J; Tzachanis D; Avigan D; Zwicker JI; Levine J; Kim M; Parker JA; Grant B; Joyce RM
Acta Haematol; 2015; 133(4):347-53. PubMed ID: 25677780
[TBL] [Abstract][Full Text] [Related]
25. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
26. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
27. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
Vose JM; Carter S; Burns LJ; Ayala E; Press OW; Moskowitz CH; Stadtmauer EA; Mineshi S; Ambinder R; Fenske T; Horowitz M; Fisher R; Tomblyn M
J Clin Oncol; 2013 May; 31(13):1662-8. PubMed ID: 23478060
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.
Zinzani PL; Rossi G; Franceschetti S; Botto B; Di Rocco A; Cabras MG; Petti MC; Stefoni V; Broccoli A; Fanti S; Pellegrini C; Montini GC; Gandolfi L; Derenzini E; Argnani L; Fina M; Tucci A; Bottelli C; Pileri S; Baccarani M
Clin Cancer Res; 2010 Aug; 16(15):3998-4004. PubMed ID: 20542986
[TBL] [Abstract][Full Text] [Related]
29. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
Dilhuydy MS; Lamy T; Foussard C; Gressin R; Casassus P; Deconninck E; Le Maignan C; Damotte D; Milpied N;
Biol Blood Marrow Transplant; 2010 May; 16(5):672-7. PubMed ID: 20045738
[TBL] [Abstract][Full Text] [Related]
30. Y
Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
[TBL] [Abstract][Full Text] [Related]
31. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Kolstad A; Laurell A; Jerkeman M; Grønbæk K; Elonen E; Räty R; Pedersen LB; Loft A; Bogsrud TV; Kimby E; Hansen PB; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Lehmann AK; Sundstrom C; Karjalainen-Lindsberg ML; Ralfkiaer E; Ehinger M; Delabie J; Bentzen H; Schildt J; Kostova-Aherdan K; Frederiksen H; Brown Pde N; Geisler CH;
Blood; 2014 May; 123(19):2953-9. PubMed ID: 24652994
[TBL] [Abstract][Full Text] [Related]
32. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
[TBL] [Abstract][Full Text] [Related]
33. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
34. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.
Vitolo U; Chiappella A; Angelucci E; Rossi G; Liberati AM; Cabras MG; Botto B; Ciccone G; Gaidano G; Falchi L; Freilone R; Novero D; Orsucci L; Pavone V; Pogliani E; Rota-Scalabrini D; Salvi F; Tonso A; Tucci A; Levis A;
Haematologica; 2009 Sep; 94(9):1250-8. PubMed ID: 19586937
[TBL] [Abstract][Full Text] [Related]
35. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
Tarella C; Zanni M; Di Nicola M; Patti C; Calvi R; Pescarollo A; Zoli V; Fornari A; Novero D; Cabras A; Stella M; Comino A; Remotti D; Ponzoni M; Caracciolo D; Ladetto M; Magni M; Devizzi L; Rosato R; Boccadoro M; Bregni M; Corradini P; Gallamini A; Majolino I; Mirto S; Gianni AM;
Leukemia; 2007 Aug; 21(8):1802-11. PubMed ID: 17554382
[TBL] [Abstract][Full Text] [Related]
36. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Hagberg H; Gisselbrecht C;
Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
[TBL] [Abstract][Full Text] [Related]
37. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Shin HJ; Lee WS; Lee HS; Kim H; Lee GW; Song MK; Kim JS; Yhim HY; Chung JS
Leuk Lymphoma; 2014 Nov; 55(11):2490-6. PubMed ID: 24432893
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
[TBL] [Abstract][Full Text] [Related]
39. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial.
Deconinck E; Lamy T; Foussard C; Gaillard F; Delwail V; Colombat P; Casassus P; Lemevel A; Brion A; Milpied N
Br J Haematol; 2000 Jun; 109(4):736-42. PubMed ID: 10929023
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
